Abstract
Background Optimal ablation technique, including catheter-tissue contact during atrial fibrillation (AF) radiofrequency (RF) ablation is associated with improved procedural outcomes. We used a custom developed software to analyze high frequency catheter position data to study the interaction between catheter excursion during lesion placement, lesion-set sequentiality and arrhythmia recurrence.
Methods 100 consecutive patients undergoing first time RF ablation for paroxysmal AF were analyzed. Spatial positioning of the ablation catheter sampled at 60 Hz during RF application was extracted from the CARTO3 system (Biosense Webster Inc., USA) and analyzed using custom developed MATLAB software to determine precise catheter spatial 3D excursion during RF ablation. The primary end point was freedom from atrial arrhythmia lasting longer than 30 seconds after a single ablation procedure.
Results At one year, 86% of patients were free from recurrent arrhythmia. There was no significant difference in clinical, echocardiographic or ablation characteristics between patients with and without recurrent arrhythmia. Analyzing 15,356,998 position data-points revealed that lesion-set sequentiality and mean lesion catheter excursion were predictors of arrhythmia recurrence. Analyzing arrhythmia recurrence by mean single-lesion catheter excursion (excursion > 2.81mm) and by sequentiality (using 46% of lesions with inter-lesion distance >6mm as cutoff) revealed significantly increased arrhythmia recurrence in the higher excursion group (23% vs. 6%, p=0.03) and in the less sequential group (24% vs. 4%, p=0.02).
Conclusion Ablation lesion sequentiality measured by catheter inter-lesion distance and catheter stability measured by catheter excursion during lesion placement are potentially modifiable factors affecting arrhythmia recurrence after RF ablation for AF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this maunscript
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available